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New Optimism Regarding 
HIV Treatment 
New insights into HIV viral 
dynamics, coupled with promising 
preliminary studies usmg new 
antiretroviral drugs and immune 
modulators has led to a renewal of 
cautious optimism for the 
management of HIV disease. 
Two independent research 
studies suggest that HIV turnover is 
much higher than previously thought, 
and that the hosts' immunological 
reserve is also much greater than had 
been appreciated. These studies, 
undertaken in individuals with CD4 
counts from -30-500, demonstrated a 
very dynamic situation with the early 
production of billions of viral 
particles with a serum half-life of 
only 2 days. When viral production 
was temporarily halted, a significant 
rise in CD 4 cells was seen. The CD4 
count doubled every 15 days when 
viral replication was interrupted by 
antiviral drugs. These studies suggest 
that immunologic reconstitution is 
possible if viral replication can be 
controlled. However, the very high 
viral turnover ensures a high mutation 
rate, leading to more rapid 
development of viral resistance to 
therapies. 
It is hoped that trials of new 
antiviral drug combinations may 
provide more effective control of viral 
replication and delay development of 
resistance. In addition to combination 
therapy regimens using different 
reverse transcriptase inhibitors, there 
is a growing interest in protease 
inhibitors. There are 4 or 5 new 
protease inhibitors that are in use or 
will soon be in Phase III trials. These 
drugs interfere with viral assembly 
·. within the host cell's cytoplasm . . 
Their effect on viral load in several 
early trials was markedly greater than 
that seen with currently available 
reverse transcriptase inhibitors. In 
addition, four different trials 
demonstrate that the combination of 
AZT with lamivudine (3TC) shows 
promise as potentially synergistic 
agents in some patients. 
While progress continues on 
the antiviral front, a report from tlu:l 
NIH on the benefits of interleukin-2 
on CD4 counts (in patients with >200 
CD4 cells) was published in the 
NEJM. Interleukin-2 therapy is costly 
and potentially toxic, but the results 
reported suggest a possible benefit of 
cytokine or anticytokine therapy in 
HIV disease. Phase III trials are 
currently underway to test the 
effectiveness of Interleukin-2, and to 
develop better tolerated cytokine 
regimens. 
The newest thrust in antiviral 
therapy for HIV is the development of 
"antisense DNA" molecules that are 
designed to attach to conserved 
regions of viral RNA, blocking 
protein production and interfering 
with viral replication. One such 
"molecular bullet" in now in phase II 
trials, and others will soon be in 
phase I trials. 
Managing the 
"Alphabet Soup" of 
Antiretroviral 
Therapy 
Four anti-retroviral drugs, all 
reverse transcriptase inhibitors, are 
currently available for treatment of 
HIV disease. In general, treatment is 
usually offered to patients with CD4 
counts of <500. 
AZT or zidovudine is the 
drug of choice for initiation of 
therapy. If AZT is not well tolerated, 
treatment with DDI or DDC is usually 
recommended. The decision of 
whether to use DDC or DDI is 
usually based on their differing 
tox1c1tles. DDI may cause pan-
creatitis, and therefore is usually 
avoided in patients with a history of 
pancreatitis or severe liver disease. 
DDC's primary toxicity is peripheral 
neuropathy. 
If a patient tolerates AZT 
well, and if the CD4 count is stable, 
no change in therapy is necessary. 
However one study suggests a benefit 
with change to DDI therapy after 4 
months of AZT even in the absence 
of clinical progression. If the CD4 
cell count is falling steadily, DDI or 
DDC may replace AZT, or be 
combined with AZT. 
Patients who have progressed 
on AZT, DDI, or DDC, may be 
switched to stavudine (D4T), the most 
recently approved reverse 
transcriptase inhibitor. 
Another reverse transcriptase 
inhibitor, 3TC (lamuvidine) looks 
promising in combination therapy 
with AZT. It is available through a 
•Cont. on page 2 
New Measures of 
Viral Load Show 
Potential Role in HIV 
Therapy 
New techniques to determine 
HIV viral load in the blood may 
facilitate the use of antiviral therapy. 
Monitoring the response of HIV 
infection to medical therapy has been 
difficult. Falling CD4 lymphocyte 
counts predict progression to AIDS 
and risk of opportunistic infections, 
but are an insensitive marker of 
antiviral response to therapy . Other 
surrogate markers such as P24 antigen 
(HIV Antigen) or Beta-2 
microglobulin levels have some 
predictive value in determining 
progress, but have not proved to be 
very effective in month to month 
monitoring of patients on antiviral 
chemotherapy. Two new techniques 
for measuring HIV viral load are now 
available, and preliminary data 
suggests they may be useful in 
assessment of antiviral therapy . Both 
techniques utilize molecular systems 
for detection of HIV RNA. The 
branched DNA assay (Chiron) and 
quantitative polymerase chain reaction 
(PCR) appear to correlate well with 
each other. Results are reported as a 
number of viral particles per volume, 
and may range from undetectable to 
millions. Long term studies using 
these assays are underway , and there is 
currently little clinical outcome data 
available. However, it is likely that 
measures of viral load will become 
part of an emerging treatment strategy 
based on assessment of an individual's 





Exposure - Update 
From CDC 
Although there is no 
prospective data on the possible 
effectiveness of AZT prophylaxis after 
needlestick exposure, a recent abstract 
from the CDC (Abstract #586 2nd 
NIH Conference on Retroviruses, 
Washington DC) of risk factors for 
serocoversion among health care 
workers with percutaneous exposure to 
HIV suggests the possibility of benefit 
with AZT use. In this multivariate 
analysis of 700 health care workers 
with exposure, risk factors for 
seroconversion included visible blood 
on the needles, deep percutaneous 
exposure, a large diameter hollow 
needle, a source patient with AIDS or 
terminal AIDS, and a lack of AZT 
prophylaxis. Prior risk studies have 
not demonstrated any benefit from 
AZT prophylaxis, and the CDC has 
reported 8 cases of health care workers 
who have now converted despite AZT 
use. The CDC currently makes no 
recommendation regarding the use of 
AZT prophylaxis. 
The usual protocol for AZT 
prophylaxis is the initiation of therapy 
as soon as possible following exposure 
(see insert) at a high dose (1200mg/d) 
for 6 weeks. A recent review from a 
NY Hospital reports on the 
acceptability of this regimen to health 
care workers (Farsiter et al. - Arch. 
Int. Med. 154: 2745-2749, 1994). 
Only 53% of health care workers 
chose to take AZT, and of those who 
did, only one-third completed the 
course of therapy . Treatment was 
discontinued (in most compassionate 
use program for patients with a CD4 
count <100. cases because of side 
effects (nausea, headache, fatigue) of 
AZT. Significant hematologic toxicity 
was not observed. 
•Cont. from page 1 
compassionate use protocol. 
Current trials are comparing 
the effectiveness of initiation of 
therapy with drug combinations versus 
monotherapy . Theoretically, 
combination therapy offers benefits 
over monotherapy in the prevention of 
viral resistance and the peliminary data 
is encouraging, but the answer is not 
yet in. Based on preliminary data, 
some clinicians choose to start all 
patients on antiviral combination 
therapy. 
It is hoped that newly 
developed tests of viral load (see 
accompanying article) will lead to 
more rational use of antiretroviral 
therapy by providing a method of 
rapidly assessing viral response to 
therapy . Until then, switching 
antiviral therapy depends primarily on 
detection of clinical changes in the 
patient that suggest failure of current 
therapy, or on the basis of a significant 





Protocol 0017 - AZT & U90 
(CD4 >200) 
Protocol 0021 - DDI & U90 
(CD4 <200) 
Protocol 0023 - DDI, AZT & 
U90 
AIDS Consultation Service, 
Portland, ME 
Compassionate Use 
AIDS Consultation Service 
& Stratogen Health 
Portland, ME 
lid. 




















Therapy for HIV 
Class of Agent Dosage 
Reverse Transcriptase 200 mg tid 
Inhibitor 
Reverse Transcriptase 2 1 OOmg tabs bid 
Inhibitor (1 hour before meals or 
2 hours after meals) 
Reverse Transcriptase 0.75mg tid 
Inhibitor 
Reverse Transcriptase 40mg po bid 
Inhibitor 
Reverse Transcriptase To be determined by 
Inhibitor on-going studies. 
(? Synergy with AZT) 
Reverse Transcriptase To be determined by 
Inhibitor on-going studies. 
(non-Nucleoside) 
Cost of Antiretroviral Therapy 
I Dosage 
200 mg tid 
200 mg bid 
Dideoxycytidine (DDC) 0.75 mg tid 
Stavudine (D4T) 40 mg bid 
• Prices base on Maine Medical Center Pharmac y as of 06/19/95 





N europathy, esophageal 
ulcer 
Neuropathy (rare) 
To be determined by 
on-going studies. 
To be determined by 
on-going studies. 





Measures of Viral Activity 
Test Use 
P24 Antigen 1. Diagnostic-neonate, primary HIV 
(HIV Antigen) syndrome 
2. Surrogate marker viral activity. 
Beta-2 Microglobulin Markers of viral activity (to follow 
response to therapy). 
CD4 Count Measure of immune functions; 
prognostic indicator. 
New Measures of Viral Load 
Branched DNA test to Monitor plasma viral load - response 
quantitate viral RNA to treatment 
Quantitative PCR Monitor plasma viral load - response 
to treatment 
Cost re resent an a rox1mate amount accordm to MMC Lab as ot 06119/95. p pp g 
Protocol for Zidovudine Prophylaxis 
for Health Care Workers 
1. Determine exposure risk. 







3. Zidovudine to start as soon as possible (at least within 72 hrs):200mg po q 4 
hrs x 6 weeks. Monitor CBC every week. 
Mike Martin is a 40 year old man 
from Southern Maine. He tested positive 
for HIV in 1988, most likely being exJ!.osed 
to the virus in 1985. He hasn't hc&'l any 
opportunistic infections associated wit'r: HIV 
and his T-cell count is about 500. 
Mike writes and edits the client 
newsletter at the AIDS Project in Portland 
called "In The Affirmative". He is also 
editing a new client information booklet at 
The AIDS Project called "Now That You 
Know You're HIV Positive". 
Mike is in a drug study at the 
AIDS Consultation Service (ACS) done with 
the UpJohn Company to test the 
effectiveness of a drug called U-90 
(Delavirdine) . 
Signing up for a drug study that is 
expected to last two years is a real 
commitment. It took me a little time and a 
lot of thinking to make my decision back 
then. It is a little over a year since the 
study began and the time has passed very 
quickly. 
The study is for a drug called U90 
(Delavirdine) and in my wing of the study 
I take it in combination with AZT. I had 
not taken any antiretrovirals before starting 
in the study as my T-cell counts were pretty 
good and I had not had any infections 
associated with HIV. So starting the study 
meant starting two drugs, 18 pills a day. 
Before starting the drug, I and my 
cohorts were interviewed, x-rayed, EKG'd, 
blood tested, and thoroughly briefed. Some 
of my cohorts take U90 in combination with 
DDI, while others of us are in the AZT 
wing. I admit that my biggest concern was 
the possible side effects of the drug. U90 
has been known to cause a rash, while AZT 
can have a nwnber of side effects such as 
headaches or nausea. To date, however, I 
have had no side effects whatsoever. 
Of course, this is a double blinded 
study so neither I nor anyone at ACS knows 
whether or not I am actually getting the 
U90. There are actually four possibilities 
concerning the U90. I could be on a low 
dose, medium dose, high dose, or placebo. 
The only sure thing is that I am getting 
AZT. 
The U90 must be taken alone 
without food for one hour before and one 
hour after taking. The AZT must be taken 
outside of these times, but can be taken 
with food. Also they should be taken 
spaced at eight hour intervals ( or pretty 
(5' 
A Patient's Perspective: In An Experimental Drug Trial 
by Mike Martin 
close to eight hours). Like all new 
medicines, the dose taking is tricky at times, 
timing the taking of each medicine and 
arranging to remember to keep up with the 
meds no matter where you are. It's tricky, 
but not impossible, and like most things, it 
is now a routine part of my life. 
One year into the stu~ my T4-
cell count and my percentage o t cells to 
total lymphocytes has stabil" d at a 
comfortable spot. The T4 count and the T4 
percentage are the two markers Dr. Smith 
and I watch, and have watched for years. 
My low T4 count was 446, my high 901 ; 
my T4% low was 24%, my high 40%. 
These have moved around over the years, 
and up until getting into the study, my T4% 
was slowly, but steadily, declining. My 
counts and percentages have stopped 
dropping and even risen a little bit. So far, 
the drug study has apparently been good for 
me. 
Of course, I had no idea or 
guarantees what would happen when I 
joined the study. It was a shot in the dark 
at that point. And even today, I don't know 
if the good results I've gotten come from 
the U90, AZT, the combination of the two, 
or just a lovely placebo effect. My guess is 
that it's the drugs that are helping, but hey, . 
I'm no doctor! 
Anyway, the blood testing and 
exams continue. At first we were tested 
weekly, then every other week, then every 
four weeks, and now we are tested every 
eight weeks. The paperwork alone is 
enough to cause a hernia. Also, I can see 
how drug testing is so expensive, as the 
rules and regulations, the testing and exams, 
and the hours of work it takes to do the 
paperwork can add up to some serious 
money. Of course, I do not get paid for 
this, nor do my cohorts. However, we do 
get free lab work (much more extensive 
than just a T4 count), and free U90 (or 
placebo), and free AZT (and/or DDI). We 
got free pill boxes and tote bags, but 
frankly, expense was spared on those items. 
Why did I decide to join the 
study? Why does anyone do this? First 
ther~ is the hwnanitarian aspect. This is a 
potentially good treatment for people with 
HIV, but we'll never know for sure until it's 
been tested. This is a chance to do good 
for people in the future. 
Second, there is the self-interest 
factor. This drug might help me (certainly 
it hasn't hurt) right now. Many of my 
cohorts are in more need of treatment than 
I@im and they joined the study with hopes 
for improvement now. My own thinking 
about my own situation was that with a 
pretty good T4 cell count and T4%, maybe 
this treatment would stop the slow, steady 
decline I was experiencing at a rer ectable 
level. I personally know of m y people 
who have lived a long time wi counts 
much lower than mine. 
Third, and equally important, I 
already knew both Dr. Smith and Sandy 
Putnam. They administer the study, and I 
knew and trusted that they would not let 
any harm come to me. I knew that they 
would be monitoring my progress and 
would let me know exactly what was 
happening. Trust is very important. 
So, in the end, I decided to join 
the U90 study for all of these reasons. It 
was a good hwnanitarian effort, might be 
good for me personally, and I felt no harm 
would come to me because I trusted the 
people doing the study. At best, it has 
helped. At worse, it would have not been 
helpful and I would have dropped out of the 
study had any adverse effects lingered. 
The results of the study have been 
mixell. )from what I have learned from my 
cohoit§, but in my case it's been a plus, so 
I will continue until the study is over. Still, 
it wasn't the easiest decision I ever made, 
and I know that people agonize over this 
kind of decision. Still, those of us who 
have been in the study a whole year have a 
sense of accomplishment and maybe even a 
little pride in what we are doing for 
ourselves and for others. In the race against 
HIV/AIDS, it is a little step toward the big 
goal. These things take time, though time 
is pressing. 
For More Information 
Regarding Experimental 
Drug Trials in New 
England. 
Call the AIDS 
Consultation Service 
Provider Hotline at : 
(800)871-2701 
World AIDS Cases 
National AIDS Cases 
National AIDS Deaths 
Maine AIDS Cases 
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"HIV in Women" 
Family Medicine Review Course 
Colby College 
Sandy Putnam, RN,MSN,FNP 
Emergency Medicine: An HIV Update 
Colby College 




Sandy T. Putnam, RN, MSN,FNP 
AIDS Update 
Emergency PA Conference 
Ramada Inn, Portland 
Robert P. Smith, MD. 
If you are providing an HIV/AIDS related educational session, please let us know at (207)871-2099. 
Maine Medical Center 
AIDS Consultation Service 
22 Bramhall Street 
Portland, ME 04102-3175 
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